These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11056241)

  • 1. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up.
    Pierce SJ; Gazvani MR; Farquharson RG
    Fertil Steril; 2000 Nov; 74(5):964-8. PubMed ID: 11056241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis.
    Kiilholma P; Tuimala R; Kivinen S; Korhonen M; Hagman E
    Fertil Steril; 1995 Nov; 64(5):903-8. PubMed ID: 7589632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
    Surrey ES; Hornstein MD
    Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial.
    Franke HR; van de Weijer PH; Pennings TM; van der Mooren MJ
    Fertil Steril; 2000 Sep; 74(3):534-9. PubMed ID: 10973651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis].
    Long QQ; Zhang SF; Han Y; Chen H; Li XL; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2010 Apr; 45(4):247-51. PubMed ID: 20646533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
    Mitwally MF; Gotlieb L; Casper RF
    Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.
    Divasta AD; Laufer MR; Gordon CM
    J Pediatr Adolesc Gynecol; 2007 Oct; 20(5):293-7. PubMed ID: 17868896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-back therapy in the treatment of endometriosis: the European experience.
    Edmonds DK
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.
    Paoletti AM; Serra GG; Cagnacci A; Vacca AM; Guerriero S; Solla E; Melis GB
    Fertil Steril; 1996 Apr; 65(4):707-10. PubMed ID: 8654625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
    Surrey ES; Voigt B; Fournet N; Judd HL
    Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
    Surrey ES; Judd HL
    J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial.
    Howell R; Edmonds DK; Dowsett M; Crook D; Lees B; Stevenson JC
    Fertil Steril; 1995 Sep; 64(3):474-81. PubMed ID: 7641897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
    Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
    J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.
    Sagsveen M; Farmer JE; Prentice A; Breeze A
    Cochrane Database Syst Rev; 2003; 2003(4):CD001297. PubMed ID: 14583930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending the treatment boundaries: Zoladex and add-back.
    Schlaff WD
    Int J Gynaecol Obstet; 1999 Feb; 64 Suppl 1():S25-31. PubMed ID: 10096462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
    Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
    J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis].
    Wang YQ; Zhang SF; Chen X; Zhu J; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):504-8. PubMed ID: 19957549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
    Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis.
    Matsuo H
    Fertil Steril; 2004 Jan; 81(1):149-53. PubMed ID: 14711558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.